197 related articles for article (PubMed ID: 21177984)
1. In vitro evaluation of potential drug-drug interactions with ticagrelor: cytochrome P450 reaction phenotyping, inhibition, induction, and differential kinetics.
Zhou D; Andersson TB; Grimm SW
Drug Metab Dispos; 2011 Apr; 39(4):703-10. PubMed ID: 21177984
[TBL] [Abstract][Full Text] [Related]
2. An in vitro evaluation of the victim and perpetrator potential of the anticancer agent laromustine (VNP40101M), based on reaction phenotyping and inhibition and induction of cytochrome P450 enzymes.
Nassar AE; King I; Paris BL; Haupt L; Ndikum-Moffor F; Campbell R; Usuki E; Skibbe J; Brobst D; Ogilvie BW; Parkinson A
Drug Metab Dispos; 2009 Sep; 37(9):1922-30. PubMed ID: 19520774
[TBL] [Abstract][Full Text] [Related]
3. In vitro characterization of the metabolic pathways and cytochrome P450 inhibition and induction potential of BMS-690514, an ErbB/vascular endothelial growth factor receptor inhibitor.
Hong H; Su H; Ma L; Yao M; Iyer RA; Humphreys WG; Christopher LJ
Drug Metab Dispos; 2011 Sep; 39(9):1658-67. PubMed ID: 21673131
[TBL] [Abstract][Full Text] [Related]
4. In vitro oxidative metabolism of cajaninstilbene Acid by human liver microsomes and hepatocytes: involvement of cytochrome p450 reaction phenotyping, inhibition, and induction studies.
Hua X; Peng X; Tan S; Li C; Wang W; Luo M; Fu Y; Zu Y; Smyth H
J Agric Food Chem; 2014 Oct; 62(43):10604-14. PubMed ID: 25272989
[TBL] [Abstract][Full Text] [Related]
5. In vitro studies investigating the interactions between degarelix, a decapeptide gonadotropin-releasing hormone blocker, and cytochrome P450.
Sonesson A; Rasmussen BB
Basic Clin Pharmacol Toxicol; 2011 Sep; 109(3):195-202. PubMed ID: 21496210
[TBL] [Abstract][Full Text] [Related]
6. Determination of unbound ticagrelor and its active metabolite (AR-C124910XX) in human plasma by equilibrium dialysis and LC-MS/MS.
Sillén H; Cook M; Davis P
J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Aug; 879(23):2315-22. PubMed ID: 21727045
[TBL] [Abstract][Full Text] [Related]
7. In vitro evaluation of the interaction potential of irosustat with drug-metabolizing enzymes.
Ventura V; Solà J; Peraire C; Brée F; Obach R
Drug Metab Dispos; 2012 Jul; 40(7):1268-78. PubMed ID: 22451700
[TBL] [Abstract][Full Text] [Related]
8. Disposition and metabolism of ticagrelor, a novel P2Y12 receptor antagonist, in mice, rats, and marmosets.
Li Y; Landqvist C; Grimm SW
Drug Metab Dispos; 2011 Sep; 39(9):1555-67. PubMed ID: 21670219
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics, pharmacodynamics, and safety of ticagrelor in volunteers with mild hepatic impairment.
Butler K; Teng R
J Clin Pharmacol; 2011 Jul; 51(7):978-87. PubMed ID: 20926753
[TBL] [Abstract][Full Text] [Related]
10. In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450s.
Prueksaritanont T; Gorham LM; Ma B; Liu L; Yu X; Zhao JJ; Slaughter DE; Arison BH; Vyas KP
Drug Metab Dispos; 1997 Oct; 25(10):1191-9. PubMed ID: 9321523
[TBL] [Abstract][Full Text] [Related]
11. In vitro inhibition and induction of human hepatic cytochrome P450 enzymes by modafinil.
Robertson P; DeCory HH; Madan A; Parkinson A
Drug Metab Dispos; 2000 Jun; 28(6):664-71. PubMed ID: 10820139
[TBL] [Abstract][Full Text] [Related]
12. In vitro assessment of cytochrome P450 inhibition and induction potential of felotaxel (SHR110008).
Ding Y; Jia Y; Lu C; Liu W; Yang J; Song Y; Zhu Y; Yang L; Ding L; Wen A
Biomed Pharmacother; 2012 Jun; 66(4):318-21. PubMed ID: 22397757
[TBL] [Abstract][Full Text] [Related]
13. Inhibitory effect of glyburide on human cytochrome p450 isoforms in human liver microsomes.
Kim KA; Park JY
Drug Metab Dispos; 2003 Sep; 31(9):1090-2. PubMed ID: 12920163
[TBL] [Abstract][Full Text] [Related]
14. Metabolism and transporter-mediated drug-drug interactions of the endothelin-A receptor antagonist CI-1034.
Sahi J; Sinz MW; Campbell S; Mireles R; Zheng X; Rose KA; Raeissi S; Hashim MF; Ye Y; de Morais SM; Black C; Tugnait M; Keller LH
Chem Biol Interact; 2006 Feb; 159(2):156-68. PubMed ID: 16356485
[TBL] [Abstract][Full Text] [Related]
15. In vitro inhibition and induction of human cytochrome P450 enzymes by mirabegron, a potent and selective β3-adrenoceptor agonist.
Takusagawa S; Miyashita A; Iwatsubo T; Usui T
Xenobiotica; 2012 Dec; 42(12):1187-96. PubMed ID: 22834478
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of time-dependent cytochrome P450 inhibition using cultured human hepatocytes.
McGinnity DF; Berry AJ; Kenny JR; Grime K; Riley RJ
Drug Metab Dispos; 2006 Aug; 34(8):1291-300. PubMed ID: 16679385
[TBL] [Abstract][Full Text] [Related]
17. Human cytochrome p450 induction and inhibition potential of clevidipine and its primary metabolite h152/81.
Zhang JG; Dehal SS; Ho T; Johnson J; Chandler C; Blanchard AP; Clark RJ; Crespi CL; Stresser DM; Wong J
Drug Metab Dispos; 2006 May; 34(5):734-7. PubMed ID: 16501008
[TBL] [Abstract][Full Text] [Related]
18. Identification of human liver cytochrome P450 enzymes involved in the metabolism of SCH 530348 (Vorapaxar), a potent oral thrombin protease-activated receptor 1 antagonist.
Ghosal A; Lu X; Penner N; Gao L; Ramanathan R; Chowdhury SK; Kishnani NS; Alton KB
Drug Metab Dispos; 2011 Jan; 39(1):30-8. PubMed ID: 20926621
[TBL] [Abstract][Full Text] [Related]
19. Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction.
Kumar GN; Dykstra J; Roberts EM; Jayanti VK; Hickman D; Uchic J; Yao Y; Surber B; Thomas S; Granneman GR
Drug Metab Dispos; 1999 Aug; 27(8):902-8. PubMed ID: 10421617
[TBL] [Abstract][Full Text] [Related]
20. Characterization of human cytochrome p450 enzymes involved in the metabolism of cilostazol.
Hiratsuka M; Hinai Y; Sasaki T; Konno Y; Imagawa K; Ishikawa M; Mizugaki M
Drug Metab Dispos; 2007 Oct; 35(10):1730-2. PubMed ID: 17646278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
